Spencer Knight的动态

查看Spencer Knight的档案

Recruiting The Future of CGT and Oncology

???????????????? ????????: AZ makes $1Billion In Vivo Cell Therapy Acquisition ?? AstraZeneca has strengthened its cell therapy portfolio with the $1B acquisition of EsoBiotec ($425M upfront), a cutting-edge clinical Belgian company pioneering in vivo immune cell engineering. ?? EsoBiotec’s ENaBL platform uses targeted lentiviruses to engineer immune cells directly inside the patient’s body, enabling faster, off-the-shelf treatments for liquid/solid tumours and autoimmune through a simple IV injection. ?????? ???????? ?????????????????????? ??????????????: - Further validates the role of in vivo cell therapies. - Demonstrates AZ commitment to expanding its cell therapy portfolio. - In vivo therapies COULD offer quicker access to treatments, showing promise in making them more accessible and cost-effective for patients. Ultimately, it's exciting to see large pharma making its second CT acquisition in a week, with AstraZeneca emphasising the exciting future of cell therapies. This steady momentum is a strong endorsement of CGTs What a great way to start the week everyone! #celltherapy #oncology #biotech #CGTweekly

  • 该图片无替代文字
Joanna Ghayad, PharmD, ACC

Certified Leadership Coach | Helping Scientists Make Bold Career Moves & Transform into Influential Leaders | 15+ Years Industry Experience

2 天前

I am super pumped to this kind of investment in in vivo cell therapy technology. will be watching this closely as it could be game changing for this therapy and patients.

Kim Wilson, MBA, CPA

Helping Tech Ops teams efficiently take new products from lab to clinic - CMC strategy and execution | Cell & Gene Therapy, Biologics

2 天前

Thanks for sharing this news. In vivo therapies could be major step forward in making innovative oncology and immune therapies more scalable, efficient, and patient-friendly - ultimately improving access. Looking forward to seeing how this technology evolves to benefit more patients.

Sateesh Babu

Associate Director l Biologics Regulatory Affairs l CMC I India Biologics Workstream Lead I Biologics l Biosimilars l Cell & Gene Therapy | RA CMC Strategy

2 天前

Thanks for sharing, Spencer. This signals a bold leap towards faster and more accessible treatments.

Brahim Gargouri Ph.D.,

Sr. Commercial BD Manager @ GenScript ProBio | Business Development, Molecular Biology

2 天前

Thanks for sharing, Spencer!

J Valencia S

China & Global Biopharma Intelligence from PharmCube

2 天前

Not only is it one of the very few cell therapy M&A deals in the last 12 months, it is also the 5th-largest announced, acconrding to our databases at PharmCube. Here's to more exciting news in the sector!

  • 该图片无替代文字
Dr. Dharmesh Patel

Cell Therapy l Gene Therapy l CMC l Process Development l Cancer Immunotherapies I Biotech Entrepreneur l Board Member I Business Consultations

2 天前

I am curious to learn more about in vivo use of Lentiviruses on cell therapy! How do we control the integration and copy numbers?

Claus Henrik Johansen

Founder and CEO Global Health Invest

2 天前

Any other list of companies doing in vivo Cell therapy ? Spencer Knight or J Valencia S ? A list would be hugely appreciated ??

Claus Henrik Johansen

Founder and CEO Global Health Invest

2 天前

Which big pharma do you think of ? Last week ?

Ariel Gioino Robman

Senior Process Engineer | Pharmaceutical & Biotech Manufacturing | DSP | Aseptic Processing

2 天前

Smart analysis

Regina Reul

Professor Process Engineering

2 天前

Interesting! Thanks for sharing Spencer Knight .

查看更多评论

要查看或添加评论,请登录